CRT defibrillator may help more heart failure patients
For patients with heart abnormalities that can't be fixed with a normal defibrillator, a cardiac resynchronization therapy with defibrillator may help with the problem. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 18, 2019 Category: Consumer Health News Source Type: news

Cardiac MRI in Patients With Cardiac Resynchronization Therapy Cardiac MRI in Patients With Cardiac Resynchronization Therapy
This article presents a strategy for conducting high quality scans safely.Europace (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 17, 2019 Category: Radiology Tags: Cardiology Journal Article Source Type: news

FDA Flags Battery Issue Impacting Some Medtronic Pacemakers
FDA alerted patients and physicians on Tuesday to a problem that may cause batteries in certain Medtronic implantable pacemakers or cardiac resynchronization therapy pacemakers (CRT-Ps) to drain more quickly than expected or without warning. Implanted pacemakers and CRT-Ps have electronics and are powered by lithium-ion batteries. One of the key electronic components is a capacitor, which stores electrical energy. Medtronic said there have been three medical device reports in which one of a Medtronic implantable pacemakers or CRT-P battery had fully drained without warning because of a crack in the ...
Source: MDDI - May 8, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

US Physicians Now Treating Patients with BIOTRONIK's Ultraslim Acticor DX Devices
Lake Oswego, Ore., April 29, 2019 /PRNewswire/ -- BIOTRONIK today announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Leading electrophysiologists throughout the United States are now treating patients with the new implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). When implanted with BIOTRONIK's Plexa ProMRI S DX lead, the hybrid ICD Acticor...This story is related to the following:Medical Devices (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - April 30, 2019 Category: Medical Devices Source Type: news

BIOTRONIK Announces First Enrollment in CRT-Next Study
BIOTRONIK has announced first enrollment in a multicenter study that aims to demonstrate that a two-lead cardiac resynchronization therapy (CRT) system with atrial sensing is at least as effective as a conventional three-lead system. BIOTRONIK's CRT-DX technology provides therapy through two ventricular leads and features a floating dipole for complete atrial diagnostics without an additional lead. (Source: eHealth News EU)
Source: eHealth News EU - January 28, 2019 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news

CRT in Heart Failure: Is the Defibrillator Needed? CRT in Heart Failure: Is the Defibrillator Needed?
Questions still remain as to the additive benefit of the defibrillator as an adjunct to cardiac resynchronization therapy.Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

BioCardia Developing Comprehensive Approach to Treat Heart Failure
It can be a bit trick when trying to put BioCardia’s cell therapy for heart failure in one specific category. Is the CardiAmp Cell Therapy a diagnostic, device, or a biologic? Perhaps it’s all of the above. The San Carlos, CA-based company’s president and CEO painted a clearer picture for the technology noting that it could play a significant role when looking at heart failure treatment. “The [CardiAMP Cell Therapy System] is regulated by the agency [FDA] as a combination product via an IDE PMA device pathway,” Peter Altman, BioCardia...
Source: MDDI - November 16, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

FDA warns Medtronic on CRM plants in Minnesota, Puerto Rico
The FDA this week released warning letters it sent to Medtronic (NYSE:MDT) over issues with cardiac rhythm management plants in Minnesota and Puerto Rico. The federal safety watchdog said inspections in April and May at both plants turned up problems related to the recall of CRM devices over high-voltage arcing, which led to the recall of some 800 implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. In January the Fridley, Minn.-based company informed physicians of the recall of 48 of the devices that were “sent through a manufacturing sequence that introduced the potential for ...
Source: Mass Device - September 12, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Medtronic Warning Letter Source Type: news

Medtronic launches ECG belt HF optimization trial
Medtronic (NYSE:MDT) said today it launched a new clinical trial evaluating the use of its ECG belt research system as a diagnostic tool for improving cardiac resynchronization therapy for heart failure patients. The Fridley, Minn.-based company said it has enrolled the first patients in the trial at Des Moines, Iowa’s Mercy Medical Center – West Lakes by principal investigator Dr. Troy Hounshell. “The aim of this technology is to give physicians immediate feedback that may impact clinical decision making at the time of implant and also during follow-up visits. By pairing CRT with the ECG Belt, we have t...
Source: Mass Device - July 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Medtronic Source Type: news

Thousands of Medtronic CRM devices need software upgrades
The FDA this week released notices from Medtronic (NYSE:MDT) warning of software issues with approximately 41,000 cardiac rhythm management devices. The warnings affect approximately 29,000 EnTrust and Escudo implantable cardioverter defibrillator devices and approximately 12,000 Percepta and Percepta Quad cardiac resynchronization therapy devices, according to urgent field notices sent out by the Fridley, Minn.-based company in June. The recalls have been labeled as Class 2 by the FDA, and no deaths have been reported related to the issues, according to Medtronic. The company said that its EnTrust and Escudo ICDs may dis...
Source: Mass Device - July 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Medtronic Source Type: news

Medtronic & #039;s Value-Based Partnerships are Paying Off in Spades
Dublin, Ireland-based Medtronic continues to lead the charge toward value-based care, and it's beginning to pay off in a big way.  One of the company's value-based care partners, UnitedHealthcare, has seen a 27% decline in the rate of preventable hospital admissions for Medtronic insulin pump users compared to patients on multiple daily insulin injections, according to an analysis of more than 6,000 members with diabetes on Medtronic MiniMed 630G and previous generation insulin pumps. And that's just in the first year of the partnership. The analysis included a mix of members using both standalone insulin pumps and pumps ...
Source: MDDI - July 11, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Size Might Matter for CRT to Work in Narrow-QRS Heart Failure Size Might Matter for CRT to Work in Narrow-QRS Heart Failure
Should cardiac resynchronization therapy indications consider ventricular size with narrower QRS intervals? It ' s ' pretty bold ' to suggest the guidelines might need revising, said an observer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

MicroPort < sup > ® < /sup > CRM Announces PMDA Approval in Japan of PLATINIUM ™ 4LV SonR < sup > ® < /sup > CRT-D < br > < span style= " font-size:14px; line-height:22px; " > < i > PLATINIUM ™ 4LV SonR* combines quadripolar IS-4 left ventricular pacing options with SonR, the world's first and only sensor-based therapeutic optimization, for cardiac resynchronization therapy. < /i > < /span >
(Source: Microport News Release)
Source: Microport News Release - June 3, 2018 Category: Medical Devices Source Type: news

Medtronic touts improved patient survival in AdaptivCRT algorithm study
Medtronic (NYSE:MDT) today released results from a study of its AdaptivCRT algorithm, touting that the use of the algorithm increased patient survival. Results from the trial were presented last week at the Heart Rhythm Society’s annual scientific sessions in Boston, the Fridley, Minn.-based company said. The AdaptivCRT algorithm is designed to personalize cardiac resynchronization therapy and adjusts how implanted CRT devices pace the heart according to evaluations of the patient’s heart rhythm, Medtronic said. In the AdaptResponse prospective registry study, researchers explored the use of the AdaptivCRT Al...
Source: Mass Device - May 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Medtronic Source Type: news

Recognizing Left Bundle Branch Block and When It Matters Recognizing Left Bundle Branch Block and When It Matters
These Mayo Clinic experts illustrate how to identify LBB on ECG, what measures to take to correct it, and novel developments in cardiac resynchronization therapy.Mayo Clinic (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 30, 2018 Category: Consumer Health News Tags: Cardiology Roundtable Source Type: news